SkyWater Technology

Phase A — Understand the business

Lens 1 · Company Overview

SkyWater is a US-headquartered (Bloomington, Minnesota), exclusively domestic, pure-play semiconductor foundry — a Delaware corp, Nasdaq: SKYT, CIK 0001819974, FY ends late December (FY2025 = 28 Dec 2025). It is one of the very few merchant foundries with a DMEA-accredited Category 1A Trusted Foundry status — it can fabricate classified / mission-critical defense and intelligence chips on US soil. That accreditation, not its process technology, is its scarcest asset.

What it actually sells — two service categories across two reportable segments:

• Advanced Technology Services (ATS) — co-development of specialized/non-standard process technologies and integration ("technology-as-a-service"); revenue is development fees + Tools (customers funding equipment that builds out SkyWater's capability). FY2025 ATS development $212.5M, Tools $28.9M.
• Wafer Services (WS) — production fab output. Two sources: Legacy SkyWater WS ($25.5M) and the newly acquired SkyWater Texas / Fab 25 ($175.3M).
• Two reportable segments: Legacy SkyWater (Minnesota fab + Kissimmee, Florida advanced-packaging via the "Center for NeoVation") and SkyWater Texas (the Austin 200mm Fab 25, 130–65nm foundational nodes, acquired and integrated in 2025).

Business model. The thesis SkyWater sells is that differentiation in semis has migrated from circuit design into process technology, materials, device physics, integration and packaging — so customers co-develop the full stack with the foundry. It targets foundational/specialty nodes (not leading-edge logic) for end-markets with multi-decade product lives: aerospace & defense, automotive, industrial automation, medical devices, energy infrastructure, and emerging computing (quantum/photonics).

Contract structure — a key weakness. SkyWater has no significant backlog; purchase orders are cancellable until shortly before production. Customers provide only 12-month rolling forecasts. Management flags explicitly that this makes revenue and margins hard to forecast and that expense levels (largely fixed fab cost) can't flex with revenue shortfalls. The Infineon Fab 25 layer is the exception — a multi-year supply agreement valued >$1B anchors the Texas output.

Lens 2 · Supply Chain

Map: specialty materials / process chemicals / gases + semiconductor capital equipment (the "Tools" customers fund) → SkyWater's three US fabs (MN 200mm + FL packaging + TX 200mm) → fabless / system customers in defense, compute, automotive, medical → end systems (defense primes, hyperscalers' bespoke silicon, quantum platforms).

Named stakeholders along the chain:

• Downstream / customers (the revenue concentration): Infineon Technologies — 43% of FY2025 revenue (the Fab 25 off-take/supply agreement); plus two other customers at 21% and 10% (FY2025); historically two leading defense-prime customers drove the ThermaView platform ramp. US DoD / intelligence agencies are the ultimate buyers behind the A&D ATS revenue.
• Upstream: capital-equipment OEMs whose tools customers fund (the "Tools" line); specialty chemical/materials/gas suppliers (single-source dependencies flagged generically in risk factors — "successful parts and materials" risk).
• Strategic counterparty: Infineon is simultaneously the seller of Fab 25, the largest customer (43%), and the >$1B supply-agreement backstop — an unusual triple-role single point of dependence.
• Acquirer (post-deal owner): IonQ — would internalize SkyWater as the fab for its ion-trap/control-ASIC/MEMS/photonics stack.

Chokepoints / single-source dependencies: (1) Infineon is the single biggest chain risk — 43% of revenue and one customer ≈ 59% of accounts receivable as of 28 Dec 2025. (2) The fabs themselves — concentrated US footprint with no offshore redundancy (a feature for Trusted-Foundry buyers, a fragility for operations/yield). (3) Capacity build depends on customer-funded Tools — when that funding completes, the Tools line collapses (it did, −62% in FY2025).

Lens 3 · Competitive Advantages (moats)

• Trusted Foundry / domestic-only footprint (the real moat). DMEA Category 1A accreditation + 100% US fabs is a regulatory/security moat: for classified defense work and for "trusted domestic supply chain" government procurement, the substitute set is tiny. This is precisely what IonQ is paying for. Durable as long as US "trusted/onshore silicon" policy persists.
• Co-development switching costs (moderate). ATS engagements embed SkyWater into a customer's process IP over multi-year cycles; once a specialty process is qualified on SkyWater's line, moving it is expensive and slow. But these are development relationships, not locked volume — and the no-backlog/cancellable-PO structure caps how much that stickiness is worth.
• Specialty / foundational-node positioning (weak-to-moderate). SkyWater deliberately avoids leading-edge (no scale to compete with TSMC/Samsung/Intel). It plays where mature, long-life, customizable processes matter. The moat here is fit, not scale — and it competes with far larger specialty foundries (Tower, GlobalFoundries, UMC, X-FAB) that have better cost curves.
• Bargaining power — weak. With 43% of revenue from one customer and ~59% of A/R from one customer, SkyWater is the price-taker in its largest relationship. Over suppliers it has little scale leverage. The negative operating cash flow and $22M cash balance further weaken its hand.

Net: the moat is regulatory (Trusted Foundry) + relationship (co-development), not economic (scale/cost). It is exactly the kind of asset worth more inside a strategic acquirer than standalone — which is the whole logic of the IonQ bid.

Lens 4 · Segments

segments.csv is empty (headers only) — so all segment numbers are pulled directly from the 10-K, labeled ``.

By service type (FY2025 vs FY2024):

The single most important fact in the financials: every legacy line declined. The headline +29% growth is entirely the bolted-on Texas fab (Infineon off-take). Strip Texas and SkyWater's organic business shrank ~22% (Legacy segment revenue fell from $342.3M to $266.8M).

By segment (FY2025):

• Legacy SkyWater: revenue $266.8M (−22%), gross profit $46.9M, net loss −$14.3M, gross margin ~18% (down from 20%).
• SkyWater Texas (since 30 Jun 2025 close): revenue $175.3M (incl. $17.9M non-cash "off-market component" of the supply agreement), gross profit $40.0M (margin ~23%), net income $137.7M — but that net income contains the $111.7M bargain-purchase gain, so it is not a run-rate.

Cause of the legacy decline: ATS development −$26.1M was driven by a $41.8M collapse in aerospace-&-defense revenue ("recent U.S. government policy shifts and changes in defense spending priorities… delayed contract awards"), partially offset by +$12.9M in advanced-compute (quantum). Tools −$47.9M because customers finished their capability-build funding cycles. So the differentiated, sticky part of the business (defense ATS) is the part that rolled over.

---

Phase B — Measure performance

Lens 5 · Earnings Result

FY2025 (10-K, FYE 28 Dec 2025):

• Revenue $442.1M, +29% YoY — but +29% is the Texas acquisition; legacy −22% (see Lens 4).
• Gross profit $86.9M, gross margin ~19.7% (cost of revenue $355.2M).
• Operating loss −$2.576M (vs +$6.56M operating income FY2024) — the operating business swung negative. SG&A jumped +56% to $74.9M (Fab 25 integration, severance, deal costs); R&D −3% to $14.6M.
• Net income $118.9M — but this is almost entirely the $111.7M bargain-purchase gain on Fab 25. Core net income ex-gain ≈ +$7.2M, itself flattered by the $17.9M non-cash off-market supply-agreement revenue.
• EPS $2.47 basic / $2.44 diluted — entirely a function of the one-time gain; ignore it as a run-rate. Underlying EPS is roughly breakeven.
• Adjusted EBITDA $53.2M, +55% (margin ~12%) — the metric management leans on; the lift is Fab 25 + the supply-agreement revenue.
• Balance-sheet / cash-flow flags (serious): cash $23.2M only; operating cash flow −$29.0M (a $47.5M swing from +$18.5M FY2024); investing −$113.0M (Fab 25 $86.5M cash + $24.3M capex); financing +$146.4M (Revolver draws of $588.7M gross in the year). FCF (OCF−capex) ≈ −$4.6M even before the acquisition. Total assets $733.9M (PP&E $511.7M, up from $165.4M — all Fab 25); total liabilities $538.1M; equity $195.8M; liabilities/equity 2.75x.

Latest quarter — Q1 FY2026 (10-Q, ended 29 Mar 2026, filed 8 May 2026):

• Revenue $160.7M (vs $61.3M Q1 FY2025 — distorted by the acquisition; Wafer Services +1,173% on $86.3M Fab 25 contribution).
• Gross profit $32.2M, gross margin ~20.0%.
• Operating loss −$5.3M — still losing money operationally.
• Interest expense $6.2M (up from $1.8M) — the Revolver debt load is now a structural drag; annualized ~$24.6M of interest against an Adj EBITDA run-rate of ~$52M → interest coverage only ~2.1x.
• Net loss −$11.2M (−$12.3M attributable to SKYT), EPS −$0.25 (vs −$0.15).
• Cash $22.2M (down from $23.2M); Adj EBITDA $13.0M.

Market reaction: decoupled from fundamentals — SKYT trades on the IonQ deal, not the print. Despite the operating loss and FTC Second Request, the stock hit an all-time high $39.93 on 2 Jun 2026 and trades ~$38.40. What's "priced in" is deal certainty + IonQ upside, not earnings.

Unusual vs own history: (1) first GAAP profit ever — but it's a non-cash bargain gain; (2) first time operating income went negative since the IPO era; (3) operating cash flow went deeply negative; (4) customer concentration leapt from "two customers 40%/20%" to "Infineon alone 43%."

Lens 6 · Earnings Calls (sentiment trend)

transcripts/ is empty — sentiment is reconstructed from filed 8-K results and press, labeled accordingly.

• Early-mid 2025: management framed DoD/budget delays as a near-term softening of ATS growth and repeatedly expressed confidence in "another record ATS revenue year in 2025 if funding delays resolve soon" — a conditional, hopeful tone. They leaned hard on quantum (>30% growth in quantum-related ATS) and the ThermaView defense platform as the offsets.
• H2 2025: pivot to the Fab 25 acquisition + Infineon >$1B supply agreement as the scale/growth narrative — "record revenues and 29% growth" became the headline, with quantum as the secular story.
• 2026 (post-deal): the standalone-company narrative effectively ended — communications shifted to merger mechanics (board recommendation, shareholder vote, FTC process).

Tone shift: from "defense delays are temporary, quantum + Texas will more than offset" (2025, defensive-optimistic) → "we are being acquired by IonQ to build the only vertically-integrated US quantum platform" (2026, sold). What they stopped saying: the confident "record ATS year" framing — because A&D revenue fell $41.8M and the organic business shrank. The recurring 2026 phrase is "trusted domestic / US-owned and US-operated."

Lens 7 · Comps

The comp that actually matters here is not a foundry peer — it is the deal. Because SKYT is a closed-vote acquisition target, the relevant "valuation" is the merger consideration, not a trading multiple:

• Deal value = $15.00 cash + $20.00 of IonQ stock = $35.00 while IonQ trades inside the $37.99–$60.13 collar. IonQ at $56.55 (19 Jun 2026) is inside the collar → deal value today ≈ $35.00.
• SKYT trades $38.40 → a +9.7% PREMIUM to the $35.00 deal value. Implied: the market expects IonQ ≈ $70 at close (above the $60.13 cap, where the fixed 0.3326 ratio lets holders ride IonQ upside) — a ~+24% IonQ move from $56.55.
• Context: at ~$1.8B equity value the deal prices SkyWater at ~4x FY2025 revenue / ~33x Adj EBITDA — a strategic multiple far above where a sub-scale, money-losing specialty foundry would trade standalone. That gap is the strategic premium IonQ is paying for Trusted-Foundry + quantum-fab vertical integration.

Lens 8 · Stock-Price Catalysts (last ~5y; mostly )

SkyWater IPO'd in 2021 at $14. The names of the moves:

• 2021 IPO + post-IPO specialty-foundry/defense enthusiasm — initial run, then a long de-rating as a small, lumpy, cash-burning foundry.
• 2024: record revenue year on defense ATS + Tools — the high-water mark for the organic story.
• 2025 — defense air-pocket: DoD budget delays / policy shifts cut A&D ATS revenue $41.8M; this is the standalone bear signal the deal later papered over.
• 26 Feb 2025 — Fab 25 acquisition announced (Infineon Austin fab + >$1B supply agreement); 30 Jun 2025 — closed, funded by a new $350M credit facility — re-rated the scale story.
• Quantum momentum (2025): >30% quantum-ATS growth; Quantum Insider flagged the "quantum bet gains momentum after Fab 25".
• 26 Jan 2026 — IonQ $35/share bid — the dominant catalyst; SKYT re-rated to the deal and then through it as IonQ stock rallied.
• 8 May 2026 — shareholders approve (overwhelming) → removes the vote condition; 24 Apr 2026 — FTC Second Request → the one overhang.
• 2 Jun 2026 — all-time high $39.93.

Pattern: pre-2026, SKYT reacted to defense-program funding and single-customer/Tools lumpiness (classic small-cap binary risk). Post-Jan-2026, it reacts almost exclusively to IonQ's stock price and FTC headlines — its beta is now to IonQ + deal risk, not to foundry fundamentals.

---

Phase C — Judge people & books

Lens 9 · Management

• Thomas Sonderman — CEO & Director (age 62), CEO since Dec 2020, board since Oct 2020; was also President Dec 2020–Sep 2023. Deep semiconductor-process pedigree (the "technology-as-a-service"/full-stack-differentiation thesis is his). Track record: took SkyWater public (2021), grew defense ATS to record 2024 revenue, then engineered the Fab 25 acquisition and the IonQ sale — i.e. delivered a liquidity event for shareholders at a strategic premium after the organic business stalled. That is the single most consequential capital-allocation outcome of his tenure.
• John Sakamoto — President & COO (age 57), since Sep 2023; runs day-to-day ops and "driving consistent profitability" — notably the period in which operating income went negative, though that reflects the defense air-pocket + integration more than execution.
• Steve Manko — CFO (age 45); Christopher Hilberg — Chief Risk & Compliance Officer / GC.
• Skin in the game: insider-transactions.csv not present — insider ownership not quantified from the research layer; n/a for precise %.
• Capital-allocation read: the defining moves are (1) the Fab 25 acquisition — paid ~$93M cash for net assets fair-valued at $318.2M (the $111.7M bargain gain), funded by debt, simultaneously securing a >$1B Infineon supply backlog — opportunistic and arguably value-creating on paper, but it ballooned leverage (L/E 2.75x) and turned operating cash flow negative; and (2) selling the whole company to IonQ at $35 after the organic story stalled — a defensible decision to crystallize a strategic premium rather than grind through a defense-spending air-pocket with $22M of cash.
• Red flags: Oxbow Realty and the Minnesota land-and-building failed sale-leaseback (treated as financing, company "deemed owner," VIE consolidated) are related-party / off-balance-sheet-flavored structures worth scrutiny — see Lens 10. No promotional-CEO pattern evident; the bigger governance question is the Infineon triple-role (seller + 43% customer + supply backstop).
• Archetype: professional/operator management (process technologist CEO), not founder-owner — consistent with a team that optimized toward a strategic exit.

Lens 10 · Forensic Red Flags

Ground: 10-K + 10-Q financials, every figure labeled.

• "Earnings" are non-cash and non-recurring. The entire $118.9M FY2025 net income is the $111.7M bargain-purchase gain; underlying operations lost money at the operating line (−$2.6M). A bargain-purchase gain (buying net assets below fair value) is real but one-time and judgment-laden — the $318.2M purchase-price allocation is explicitly "preliminary and subject to further adjustment," so the gain could be revised. Treat FY2025 GAAP profitability as an accounting artifact.
• Non-cash revenue inside the headline. $17.9M of the $175.3M Texas revenue is the non-cash "off-market component" of the Infineon supply agreement — it flatters both revenue and Adj EBITDA without cash coming in.
• Cash flow diverges hard from earnings. GAAP net income +$118.9M while operating cash flow was −$29.0M — a ~$148M gap, the cleanest tell that the profit is non-cash.
• Liquidity is thin and debt-funded. $22–23M cash against negative operating cash flow; the business runs on the $350M Revolver (matures Jun 2030; $588.7M gross draws in FY2025). Management states the Revolver "will provide sufficient liquidity to fund operations for the next twelve months… however, we may need to seek additional financing and cannot provide any assurance" — i.e. conditional going-concern comfort, not unconditional. No formal going-concern doubt was raised.
• Off-balance-sheet / VIE / related-party structures: the Minnesota failed sale-leaseback (deemed owner, financing obligation) and Oxbow Realty (consolidated VIE: total assets $43.9M, debt $33.5M) add hidden leverage and complexity. Worth a forensic line-item, especially the financing obligations.
• SBC / non-GAAP gap: Adj EBITDA strips equity comp and "reorganization/severance" — standard, but the $53.2M Adj EBITDA vs −$2.6M operating loss spread shows how much depreciation + add-backs flatter the non-GAAP figure.
• Receivables concentration: one customer ≈ 59% of accounts receivable at year-end — a collection/counterparty concentration risk.

Regulatory findings (required sub-section).

• SEC Litigation Releases: None — 0 LR naming SkyWater 2021-06-20→2026-06-20.
• SEC AAERs: None — 0 AAER in the period.
• 10-K Item 3 (Legal Proceedings): no material litigation disclosed — Item 3 carries no substantive content beyond the heading.
• Non-SEC enforcement (web): the only material regulatory action against the company is the FTC HSR Second Request (24 Apr 2026) on the IonQ merger — an antitrust review of the deal, not an enforcement/penalty against SkyWater's conduct. No FTC/DOJ/FDA/CFPB fines, consent decrees, or settlements surfaced.
• Conclusion: No material accounting-fraud or enforcement findings — verified via SEC EDGAR EFTS (LR, AAER), web search, and 10-K Item 3 as of 2026-06-20. The forensic concerns are quality-of-earnings (non-cash gain, non-cash revenue, negative operating cash flow, VIE/sale-leaseback leverage), not fraud.

---

Phase D — Project & stress-test

Lens 11 · Forward Projection

This is a deal-stub, so the meaningful "projection" is the consideration payoff, not a standalone EPS path. I give both, clearly labeled.

(a) Deal-value projection (the live trade) — output: Per-share consideration = $15.00 cash + IonQ stock leg, where the stock leg = $20.00 fixed when IonQ's 20-day VWAP (3 biz days pre-close) is between $37.99 and $60.13; = 0.3326 × VWAP above $60.13; = 0.5265 × VWAP below $37.99.

Base case: deal closes Q3 2026 with IonQ in the collar → holders receive ~$35.00; buying at $38.40 loses ~9% unless IonQ rallies above ~$70 before close. Bull case: IonQ runs past the $60.13 cap (quantum momentum continues; IonQ already +755% YoY Q1 revenue, raised FY26 guide to $260–270M) → stub worth $38–43. Bear case: FTC blocks/forces a re-cut, or IonQ stock falls below the floor → SKYT collapses toward standalone fair value (well below $35; a money-losing sub-scale foundry on $22M cash would not hold a $1.8B cap), a >35% drawdown from $38.40.

(b) Standalone EPS (the break-case floor) — output: If the deal broke, the run-rate is roughly breakeven-to-small-loss EPS: FY2025 underlying (ex-gain) net income ~$7.2M / ~48.7M diluted shares ≈ $0.15 "core" EPS, but Q1 FY2026 ran a −$0.25 loss as interest expense ($6.2M/qtr) and the defense air-pocket bit. A standalone FY2026 would plausibly print a small GAAP loss (negative operating margin + ~$24.6M annual interest vs ~$52M Adj EBITDA), with Texas/Infineon volume the swing factor.

Forecast log: Skipped per --watchlist rule (log a Brier forecast only on a genuine committed base case; do not create in the loop). The scoreable proposition if logged would be binary on deal completion ("SKYT/IonQ merger closes by 2026-12-31"), not an EPS line — appropriate for /thesis, not here.

Lens 12 · Bull vs Bear

Bull case (for owning SKYT at $38.40). The deal is closed-vote and strategically logical: IonQ needs a domestic, Trusted-Foundry, quantum-capable fab to vertically integrate (pull forward its 200,000-qubit QPU testing to 2028) and to qualify for US-government/defense procurement. A vertical deal (no horizontal foundry overlap) is hard for the FTC to block — Second Requests on vertical deals usually end in clearance with timing extension, not prohibition. With the stock leg uncapped above $60.13 and IonQ on a quantum tear (+755% YoY revenue, Strong Buy, $67.64 avg target ), SKYT is a leveraged long-IonQ call with a $15 cash floor — if IonQ runs to $70–85, the stub is worth $38–43 and you collected optionality cheaper than buying IONQ outright.

Bear case (2–3 things that permanently impair / lose money). (1) You are paying a +10% premium to a $35 deal — the base case is a negative-9% return unless IonQ rallies ~24%+. (2) FTC Second Request is a real overhang — even a clearance pushes close into Q3+ (time decay on the cash leg; risk of a IonQ-stock-driven re-cut). A break sends SKYT toward standalone value, and standalone is a sub-scale foundry that lost money operationally, burned cash, runs on a Revolver with $22M of cash, and just lost $41.8M of its stickiest (defense) revenue with 43% single-customer dependence — a >35% air-pocket. (3) The stub's downside below the $37.99 floor is IonQ's downside (0.5265 ratio): IonQ is a richly-valued, pre-profit quantum name with an $25.89–$84.64 52-week range — a 30%+ IonQ drawdown before close drags the stub under $30 even if the deal completes.

Pre-mortem (18 months out, thesis broke): FTC's Second Request dragged into Q4 2026; IonQ's quantum momentum cooled and the stock fell to the high-$30s/low-$40s; either the deal closed near the floor (holders got $30–33, a loss from $38.40) or, worse, the parties re-cut/terminated on the antitrust timeline and SKYT re-rated to standalone ($10–15 zone given the cash burn and lost defense revenue) — a ~60% loss from the premium entry.

Are multiples too high? As a standalone, unquestionably — ~4x sales / ~33x Adj EBITDA for a money-losing specialty foundry is a strategic-takeout multiple, not a fundamental one. As a stub, the question isn't the multiple but (IonQ price × ratio) + $15 vs the price you pay — and at $38.40 you're paying for IonQ upside you don't yet have.

Contrarian view (what the market is refusing to see): the crowd is treating SKYT at an all-time high as "deal certainty + IonQ rocket." What it's under-pricing is that at $38.40 the arb is negative against the $35 base case — you are not clipping a discount, you are paying up for a leveraged IonQ bet while wearing FTC-break risk whose downside is a cash-burning, customer-concentrated, defense-exposed foundry. The asymmetry has quietly flipped against new longs.

Lens 13 · Devil's Advocate (short-seller)

Dismantling the long. (1) Revenue concentration is grotesque and worsening — Infineon 43%, top-3 = 74%, one customer = 59% of A/R. The "growth" is one acquired off-take contract; lose or reprice Infineon and the P&L caves. (2) The moat bulls cite is the defense/Trusted-Foundry base — and that base just shrank $41.8M on government-spending shifts; the sticky part is the weak part. (3) The most dangerous competitors bulls underestimate: Tower, GlobalFoundries (which just bought AMF to lead silicon photonics ), UMC, X-FAB — all larger, better cost curves, also chasing specialty/photonics/quantum-adjacent work; SkyWater's only defensible edge is the accreditation, not the technology. (4) Worst capital-allocation optics: debt-funded acquisition that turned operating cash flow negative + VIE/failed-sale-leaseback financing structures + a related-party-flavored Infineon triple-role. (5) Assumptions that must hold for $38.40: the FTC clears and IonQ trades above ~$70 at close and nothing in the supply agreement / Texas ramp disappoints in the interim. (6) If growth disappoints 20–30% standalone: with negative operating margins and fixed fab cost + ~$24.6M interest, a 20–30% revenue miss pushes the company into meaningful losses and tighter Revolver covenant headroom. (7) Single scenario that permanently impairs: FTC forces termination → SKYT standalone with $22M cash, negative op cash flow, lost defense revenue, and 43% customer concentration must either dilute or lever further — a plausible 50–60% equity impairment from the current premium. Plausibility: low-but-not-trivial (vertical deal, but extended FTC reviews occasionally end in abandonment).

Lens 14 · Management Questions (15, ordered by information value)

1. FTC Second Request: what specific theory of harm is the FTC probing in a vertical quantum-platform/foundry deal, and what is your realistic timeline + any divestiture/behavioral remedy you'd accept to clear it?
2. If the FTC review extends past the merger agreement's outside date, what are the termination rights, the break-fee mechanics, and each party's incentive to extend vs. walk?
3. Standalone contingency: if the deal terminates, what is the 12-month liquidity plan given $22M cash, negative operating cash flow, and the $350M Revolver — would you need to raise equity, and at what dilution?
4. Infineon is 43% of revenue, ~59% of A/R, the Fab 25 seller, and the >$1B supply backstop. What are the volume commitments vs. forecasts under the supply agreement, the pricing reset terms, and your exposure if Infineon underships?
5. The $41.8M aerospace-&-defense revenue decline — is that a permanent reset in program scope or a timing air-pocket, and what is the funded-backlog visibility into FY2026?
6. The $111.7M bargain-purchase gain is "preliminary." What could revise it, and what's the cash vs. non-cash split of Fab 25's contribution on a steady-state basis?
7. Operating income went negative in FY2025 and Q1 FY2026. What is the path to operating (not Adjusted-EBITDA) profitability, and the revenue level required for fab-utilization breakeven at Texas?
8. Interest expense is now ~$24.6M annualized against ~$52M Adj EBITDA. What are the Revolver covenants (leverage/coverage), current headroom, and the sensitivity to a revenue shortfall?
9. The "Tools" line fell 62% as customers finished funding cycles. Is Tools structurally lower now, and what does that imply for ATS-development cadence in FY2026?
10. Walk through the Oxbow Realty VIE and the Minnesota failed sale-leaseback: total financing obligations, cash payments, and why these structures vs. conventional financing?
11. Quantum-related ATS grew >30%. How large is that book in dollars today, what's its margin profile, and how much is IonQ-related vs. other quantum customers?
12. Customer-funded capacity build (Tools) vs. company-funded capex — what is the FY2026 capex plan, the funding source, and the utilization assumption behind it?
13. Beyond Infineon and the two ~21%/10% customers, what is the concrete diversification pipeline, and what revenue would the next 12 months add from new logos?
14. Insider ownership and alignment: what is management/board ownership, and how does the IonQ consideration treat unvested equity and change-of-control payments?
15. Post-close (if IonQ completes): what changes for the existing Infineon/defense customer relationships under IonQ ownership — any contractual change-of-control or trusted-foundry-accreditation continuity risk?

---